Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


05.08.2019

4 AJR Am J Roentgenol
1 Am J Respir Crit Care Med
1 Anticancer Res
1 BMC Cancer
1 Br J Cancer
3 Cancer Res
2 Cancer Sci
1 Clin Exp Metastasis
1 Clin Lung Cancer
1 Clin Nucl Med
2 Eur J Cardiothorac Surg
1 Int J Cancer
1 Int J Oncol
2 J Cancer Res Clin Oncol
2 J Clin Oncol
9 J Thorac Oncol
2 Lung Cancer
1 Lung Cancer (Auckl)
4 PLoS One
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. CHEN L, Smith DA, Somarouthu B, Gupta A, et al
    A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies.
    AJR Am J Roentgenol. 2019 Jul 30:1-12. doi: 10.2214/AJR.19.21135.
    PubMed     Text format     Abstract available

  2. KANDATHIL A, Iii RCS, Subramaniam RM
    Lung Cancer Recurrence: (18)F-FDG PET/CT in Clinical Practice.
    AJR Am J Roentgenol. 2019 Jul 30:1-9. doi: 10.2214/AJR.19.21227.
    PubMed     Text format     Abstract available

  3. GRUDEN JF, Green DB
    Reply to "Appropriate Timing for Follow-Up CT Imaging for Stable Lung CT Screening Reporting and Data System Category 3 Lesions Identified at Baseline Low-Dose CT".
    AJR Am J Roentgenol. 2018;211:W302.
    PubMed     Text format    

  4. PANSE PM, Cummings KW, Gotway MB
    Appropriate Timing for Follow-Up CT Imaging for Stable Lung CT Screening Reporting and Data System Category 3 Lesions Identified at Baseline Low-Dose CT.
    AJR Am J Roentgenol. 2018;211:W301.
    PubMed     Text format    


    Am J Respir Crit Care Med

  5. FISCH AS, Fintelmann FJ, Garcia-Moliner ML, Gaissert HA, et al
    Systemic Amyloidosis Mimicking Lung Cancer.
    Am J Respir Crit Care Med. 2019 Jul 26. doi: 10.1164/rccm.201812-2261.
    PubMed     Text format    


    Anticancer Res

  6. KOTSANTIS I, Economopoulou P, Psyrri A, Maratou E, et al
    Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:4185-4190.
    PubMed     Text format     Abstract available


    BMC Cancer

  7. YU H, Sun J, Zhao C, Wang H, et al
    SET domain containing protein 5 (SETD5) enhances tumor cell invasion and is associated with a poor prognosis in non-small cell lung cancer patients.
    BMC Cancer. 2019;19:736.
    PubMed     Text format     Abstract available


    Br J Cancer

  8. LAHEURTE C, Dosset M, Vernerey D, Boullerot L, et al
    Distinct prognostic value of circulating anti-telomerase CD4(+) Th1 immunity and exhausted PD-1(+)/TIM-3(+) T cells in lung cancer.
    Br J Cancer. 2019 Jul 30. pii: 10.1038/s41416-019-0531.
    PubMed     Text format     Abstract available


    Cancer Res

  9. CHANG YC, Chiou J, Yang YF, Su CY, et al
    Therapeutic Targeting of Aldolase A Interactions Inhibits Lung Cancer Metastasis and Prolongs Survival.
    Cancer Res. 2019 Jul 29. pii: 0008-5472.CAN-18-4080.
    PubMed     Text format     Abstract available

  10. XIE M, Zheng H, Madan-Lala R, Dai W, et al
    MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer.
    Cancer Res. 2019 Jul 30. pii: 0008-5472.CAN-19-0698.
    PubMed     Text format     Abstract available

  11. BROUWER AF, Eisenberg MC, Meza R
    Case Studies of Gastric, Lung, and Oral Cancer Connect Etiologic Agent Prevalence to Cancer Incidence.
    Cancer Res. 2018;78:3386-3396.
    PubMed     Text format     Abstract available


    Cancer Sci

  12. KITAZONO S, Sakai K, Yanagitani N, Ariyasu R, et al
    Barcode sequencing identifies resistant mechanisms to EGFR-inhibitors in circulating tumor DNA of lung cancer patients.
    Cancer Sci. 2019 Jul 30. doi: 10.1111/cas.14153.
    PubMed     Text format     Abstract available

  13. MATSUMOTO Y, Sawa K, Fukui M, Oyanagi J, et al
    Impact of tumor microenvironment on the efficacy of EGFR-TKIs in patients with EGFR-mutant non-small cell lung cancer.
    Cancer Sci. 2019 Aug 1. doi: 10.1111/cas.14156.
    PubMed     Text format     Abstract available


    Clin Exp Metastasis

  14. CARBONE F, Grossi F, Bonaventura A, Vecchie A, et al
    Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.
    Clin Exp Metastasis. 2019 Aug 2. pii: 10.1007/s10585-019-09984.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  15. ZHAO Y, Zhang B, Wang S, Qiao R, et al
    Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
    Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30155.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  16. SENIARAY N, Verma R, Belho E, Malik D, et al
    Diffuse Pulmonary Metastases From Prostate Cancer on 68Ga PSMA PET/CT.
    Clin Nucl Med. 2019 Jul 29. doi: 10.1097/RLU.0000000000002753.
    PubMed     Text format     Abstract available


    Eur J Cardiothorac Surg

  17. OLLAND A, Falcoz PE
    Complex segmentectomy in the treatment of stage IA non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2019 Aug 1. pii: 5542615. doi: 10.1093.
    PubMed     Text format    

  18. DENG HY, Tang X, Zhou Q
    Sublobar resection: an alternative to lobectomy in treating stage I non-small-cell lung cancer?
    Eur J Cardiothorac Surg. 2019 Jul 25. pii: 5538725. doi: 10.1093.
    PubMed     Text format    


    Int J Cancer

  19. GURTNER K, Kryzmien Z, Koi L, Wang M, et al
    Radioresistance of KRAS/TP53-Mutated Lung Cancer can be overcome by Radiation Dose Escalation or EGFR Tyrosine Kinase Inhibition In Vivo.
    Int J Cancer. 2019 Jul 29. doi: 10.1002/ijc.32598.
    PubMed     Text format     Abstract available


    Int J Oncol

  20. JIANG L, Li Z, Wang R
    Long noncoding RNAs in lung cancer: Regulation patterns, biologic function and diagnosis implications (Review).
    Int J Oncol. 2019 Jul 29. doi: 10.3892/ijo.2019.4850.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  21. HAKOZAKI T, Okuma Y, Hashimoto K, Hosomi Y, et al
    Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.
    J Cancer Res Clin Oncol. 2019 Jul 26. pii: 10.1007/s00432-019-02985.
    PubMed     Text format     Abstract available

  22. HOTZEL J, Melling N, Muller J, Polonski A, et al
    Protein expression of close homologue of L1 (CHL1) is a marker for overall survival in non-small cell lung cancer (NSCLC).
    J Cancer Res Clin Oncol. 2019 Aug 1. pii: 10.1007/s00432-019-02989.
    PubMed     Text format     Abstract available


    J Clin Oncol

  23. JAGSI R, Griffith KA, Bellon JR, Woodward WA, et al
    Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.
    J Clin Oncol. 2018 Mar 20:JCO2017772665. doi: 10.1200/JCO.2017.77.2665.
    PubMed     Text format     Abstract available

  24. RAMALINGAM SS, Dahlberg SE, Belani CP, Saltzman JN, et al
    Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.
    J Clin Oncol. 2019 Jul 30:JCO1901006. doi: 10.1200/JCO.19.01006.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  25. ZWITTER M, Cufer T, Vrankar M, Kern I, et al
    Lung Cancer in Slovenia.
    J Thorac Oncol. 2019;14:1327-1331.
    PubMed     Text format    

  26. ZHOU H, Liu J, Zhang Y, Huang Y, et al
    Autoimmune Diseases and Lung Cancer: A Mendelian Randomization Study.
    J Thorac Oncol. 2019;14:e161-e163.
    PubMed     Text format    

  27. WATANABE Y, Kikuchi R, Iwai Y, Ito M, et al
    Varicella Zoster Virus Encephalitis Mimicking Nivolumab-Induced Autoimmune Neuropathy in a Patient with Lung Cancer.
    J Thorac Oncol. 2019;14:e163-e165.
    PubMed     Text format    

  28. JAIN A, Fujioka N, Patel M
    Immune Checkpoint Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer: A Report of Two Cases.
    J Thorac Oncol. 2019;14:e165-e167.
    PubMed     Text format    

  29. STIRLING R, Zalcberg J
    Peeling the Onion of Health Care Disparity in Lung Cancer.
    J Thorac Oncol. 2019;14:e167-e168.
    PubMed     Text format    

  30. CONDE E, Hernandez S, Martinez R, Angulo B, et al
    Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.
    J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30562.
    PubMed     Text format     Abstract available

  31. YANG SC, Kuo CW, Lai WW, Lin CC, et al
    Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up.
    J Thorac Oncol. 2019 Jul 25. pii: S1556-0864(19)30588.
    PubMed     Text format     Abstract available

  32. MAKIMOTO G, Ohashi K, Tomida S, Nishii K, et al
    Brief Report: Rapid Acquisition of Alectinib Resistance in ALK-positive Lung Cancer with High Tumor Mutation Burden.
    J Thorac Oncol. 2019 Jul 30. pii: S1556-0864(19)30602.
    PubMed     Text format     Abstract available

  33. BERNICKER EH, Quigley EMM
    The Gut Microbiome Influences Responses to Programmed Death 1 Therapy in Chinese Lung Cancer Patients - the Benefits of Diversity.
    J Thorac Oncol. 2019;14:1319-1322.
    PubMed     Text format    


    Lung Cancer

  34. WANG X, Leader JK, Wang R, Wilson D, et al
    Erratum to "Vasculature surrounding a nodule: A novel lung cancer biomarker" [Lung Cancer 114 (December) (2017) 38-43].
    Lung Cancer. 2019 Jul 26. pii: S0169-5002(19)30560.
    PubMed     Text format    

  35. STEFFENS CC, Elender C, Hutzschenreuter U, Dille S, et al
    Corrigendum to "Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study" [Lung Cancer 130 (2019) (April) 216-225].
    Lung Cancer. 2019 Jul 22. pii: S0169-5002(19)30555.
    PubMed     Text format    


    Lung Cancer (Auckl)

  36. MASYKURA N, Zaini J, Syahruddin E, Andarini SL, et al
    Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients.
    Lung Cancer (Auckl). 2019;10:57-66.
    PubMed     Text format     Abstract available


    PLoS One

  37. LUNG J, Hung MS, Lin YC, Lee KF, et al
    MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population.
    PLoS One. 2019;14:e0220670.
    PubMed     Text format     Abstract available

  38. EDAHIRO R, Kanazu M, Kurebe H, Mori M, et al
    Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
    PLoS One. 2019;14:e0220570.
    PubMed     Text format     Abstract available

  39. CHEN Y, Watson TR, Criss SD, Eckel A, et al
    A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea.
    PLoS One. 2019;14:e0220610.
    PubMed     Text format     Abstract available

  40. DONG J, Zhu D, Tang X, Lu D, et al
    Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
    PLoS One. 2019;14:e0220306.
    PubMed     Text format     Abstract available


    Thorax

  41. O'DOWD EL, Ten Haaf K
    Lung cancer screening: enhancing risk stratification and minimising harms by incorporating information from screening results.
    Thorax. 2019 Jul 30. pii: thoraxjnl-2019-213156.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: